Thermo Fisher Scientific Inc.

NYSE:TMO Stock Report

Market Cap: US$160.1b

Thermo Fisher Scientific Past Earnings Performance

Past criteria checks 5/6

Thermo Fisher Scientific has been growing earnings at an average annual rate of 1.4%, while the Life Sciences industry saw earnings growing at 4.5% annually. Revenues have been growing at an average rate of 8% per year. Thermo Fisher Scientific's return on equity is 13.2%, and it has net margins of 15.2%.

Key information

1.4%

Earnings growth rate

2.2%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate8.0%
Return on equity13.2%
Net Margin15.2%
Last Earnings Update29 Mar 2025

Recent past performance updates

Recent updates

Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In

Apr 24

Weekly Picks: 📈 3 stocks that could thrive during stagflation

Apr 24
Weekly Picks: 📈 3 stocks that could thrive during stagflation

Thermo Fisher Scientific And Its Real Value

Apr 14
author-image

The demand for personalized medicine will keep Thermo Fisher Scientific thriving

Mar 18Resilient Demand for Life Sciences & Diagnostics – TMO is a key supplier for biotech, pharma, and research institutions, ensuring steady demand despite economic cycles.

Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences

Mar 07

Earnings Preview: Thermo Fisher Is Facing Way Too Many Headwinds

Jan 29

Biologicals Is The Future In Thermo Fisher: Buy Rating

Jan 22

An Intrinsic Calculation For Thermo Fisher Scientific Inc. (NYSE:TMO) Suggests It's 31% Undervalued

Jan 18
An Intrinsic Calculation For Thermo Fisher Scientific Inc. (NYSE:TMO) Suggests It's 31% Undervalued

Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?

Dec 31
Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?

Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Not Quite Adding Up

Dec 13
Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Not Quite Adding Up

Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic

Dec 10

Thermo Fisher: M&A And Innovation To Drive Sales Growth

Dec 04

Thermo Fisher Scientific: Near The Bottom And Attractively Valued

Nov 14

Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'

Oct 23

Thermo Fisher Scientific: Fantastic Company, Rich Valuation

Oct 04

These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well

Sep 21
These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well

Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings

Aug 16
Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings

Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging

Jul 25

A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)

Jul 11
A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)

Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?

Jun 18
Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?

Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends

Jun 07

Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)

Apr 30

Revenue & Expenses Breakdown

How Thermo Fisher Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:TMO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
29 Mar 2542,8986,5148,5901,401
31 Dec 2442,8796,3358,5951,390
28 Sep 2442,3706,1358,5121,343
29 Jun 2442,3466,2208,4691,316
30 Mar 2442,4926,0348,4341,322
31 Dec 2342,8575,9958,3811,337
30 Sep 2343,4215,9418,4641,401
01 Jul 2343,5245,7218,6531,433
01 Apr 2343,8076,0248,7811,453
31 Dec 2244,9156,9508,9401,471
01 Oct 2244,1677,0328,8541,472
02 Jul 2242,8207,4398,6111,472
02 Apr 2241,1237,6038,3171,450
31 Dec 2139,2117,7257,8571,406
02 Oct 2139,0598,5657,8431,390
03 Jul 2138,2508,5967,4621,335
03 Apr 2135,8947,9247,1991,256
31 Dec 2032,2186,3756,9401,181
26 Sep 2028,4974,8796,3601,067
27 Jun 2026,2483,7066,2921,018
28 Mar 2025,6473,6696,1141,000
31 Dec 1925,5423,6966,1391,003
28 Sep 1925,2203,5926,060992
29 Jun 1924,8683,5416,025985
30 Mar 1924,6303,1746,033981
31 Dec 1824,3582,9386,022967
29 Sep 1823,8982,5706,022949
30 Jun 1823,0942,3955,888926
31 Mar 1822,0062,2565,632906
31 Dec 1720,9182,2285,428887
30 Sep 1719,8242,3305,214867
01 Jul 1719,1992,2705,064833
01 Apr 1718,7442,1744,999794
31 Dec 1618,2742,0254,883754
01 Oct 1617,9731,9994,814723
02 Jul 1617,6062,0034,711711
02 Apr 1617,3411,9984,639703
31 Dec 1516,9651,9804,566692
26 Sep 1516,8061,9784,633695
27 Jun 1516,8541,9714,732698
28 Mar 1516,9051,7384,823707
31 Dec 1416,8901,8964,788691
27 Sep 1415,8641,6354,415613
28 Jun 1414,8841,4824,031534

Quality Earnings: TMO has high quality earnings.

Growing Profit Margin: TMO's current net profit margins (15.2%) are higher than last year (14.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TMO's earnings have grown by 1.4% per year over the past 5 years.

Accelerating Growth: TMO's earnings growth over the past year (8%) exceeds its 5-year average (1.4% per year).

Earnings vs Industry: TMO earnings growth over the past year (8%) exceeded the Life Sciences industry -4.1%.

Return on Equity

High ROE: TMO's Return on Equity (13.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/28 07:12
End of Day Share Price 2025/04/28 00:00
Earnings2025/03/29
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thermo Fisher Scientific Inc. is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kadambari DaptardarAccountability Research Corporation
David ToungArgus Research Company
Catherine Ramsey SchulteBaird